You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2024

Claims for Patent: 6,187,341

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,187,341

Title:	Trovafloxacin mesylate tablet
Abstract:	Compositions, especially in the form of tablets containing the polymorph II form of trovafloxacin mesylate, a lubricant, and microcrystalline cellulose (MC) as the diluent. Such compositions employing MC as a diluent exhibit good storage stability properties and dissolution.
Inventor(s):	Johnson; Alton D. (New York, NY), Sinko; Christopher M. (Niantic, CT)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	09/233,823
Patent Claims:	1. A dry granulated composition comprising the polymorph II form of trovafloxacin mesylate, a lubricant, and at least 5% of microcrystalline cellulose (MC). 2. A composition as defined in claim 1, in the form of a tablet. 3. A composition as defined in claim 1 which passes USP, .sub.23 rd Edition, Stage 1 (S.sub.1) acceptance criteria. 4. A composition as defined in claim 2, further comprising a film coating. 5. A composition as defined in claim 4, wherein said coating comprises hydroxypropyl cellulose. 6. A composition as defined in claim 1, comprising at least 20% by weight of microcrystalline cellulose. 7. A composition as defined in claim 6, comprising at least 30% by weight of microcrystalline cellulose. 8. A composition as defined in claim 2, further comprising a disintegrant. 9. A composition as defined in claim 2, having a hardness of at least 8 kP. 10. A composition of matter comprising trovafloxacin mesylate in the form of a pharmaceutical tablet which, after having been stability tested by being stored for 12 weeks in an open container at constant conditions of 40.degree. C and 75% relative humidity, exhibits the following degradant levels: A. less than 0.5% by weight of each of N-stearoyltrovafloxacin and N-palimitoyltrovafloxacin; B. less than 0.2% by weight of any other degradant; and C. the total of (A)+(B) is less than 1.0% by weight. 11. A composition as defined in claim 10, further comprising a film coating. 12. A composition as defined in claim 11, wherein said coating comprises hydroxypropyl cellulose. 13. A composition as defined in claim 10, comprising at least 5% by weight of microcrystalline cellulose. 14. A composition as defined in claim 13, comprising at least 20% by weight of microcrystalline cellulose. 15. A composition as defined in claim 14, comprising at least 30% by weight of microcrystalline cellulose. 16. A composition comprising TBL Component %, w:w Trovafloxacin Mesylate* 52.7 Microcrystalline Cellulose 36.8 Sodium Croscarmellose 4.8 Magnesium Stearate 1.9 Film Coating 3.8 *polymorph II

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.